TVRD
Tvardi Therapeutics Inc
NASDAQ · Pharmaceuticals
$3.72
+0.17 (+4.79%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.10M | 10.81M | 8.76M |
| Net Income | 2.81M | 2.98M | 1.76M |
| EPS | — | — | — |
| Profit Margin | 25.3% | 27.6% | 20.0% |
| Rev Growth | -6.6% | +19.2% | +16.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 8.61M | 10.02M | 11.15M |
| Total Equity | 10.12M | 11.02M | 11.87M |
| D/E Ratio | 0.85 | 0.91 | 0.94 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 4.19M | 3.89M | 3.58M |
| Free Cash Flow | 2.70M | 2.37M | 1.91M |